Hepatitis C: topical and comprehensive seminar
Posted on April 6, 2015
The Lancet has published a topical and comprehensive seminar on hepatitis C
The March 2015 issue of the Lancet contains an authoritative seminar on hepatitis C (Webster DP, et al. Lancet. 2015;385:1124-1135). The Lancet is one of the world’s leading medical journals; an independent and authoritative voice in global medicine. Dr. Daniel Webster and colleagues’ comprehensive HCV seminar includes discussion on the topics of hepatitis C virology, immunology, epidemiology, diagnosis, acute HCV, natural history, and treatment. The main goal of treatment for chronic HCV is cure, and thus prevention of disease progression. Indications for treatment are addressed in this seminar, as well as the following:
- Treatment for genotype 1
- Interferon-sparing regimens with new agents for genotype 1
- Interferon-free regimens for genotype 1
- Treatment for genotypes 2–6
- Interferon-sparing regimens for genotypes 2–6
- Interferon-free regimens for genotypes 2 and 3
- Patients with HIV/HCV co-infection
- Patients with decompensated cirrhosis or undergoing liver transplantation
The authors conclude that while improved, efficacious, and simplified interferon-free and, for most patients, ribavirin-free treatments for HCV infection are now available, meeting the demand for therapy of a common disease with breakthrough direct-acting antiviral therapies is concerning for policy makers because of the immediate budgetary effect. The high cost of therapies might reduce access, thus restricting societal benefit. Stratification and prioritization of patients on the basis of cost-effectiveness, stage of disease, and potential gain from treatment might be needed.
This review article is available for free for a limited time in the primary care provider section of the American Journal of Medicine Hepatitis C Resource Center. Click here!
The Lancet Infectious Diseases is hosting its inaugural Viral Hepatitis Summit in Shanghai (April 10–12). The goal of this Summit is to address the increasingly urgent need for a global plan to eliminate hepatitis C. “With no vaccine in sight, if we are truly to contemplate elimination of hepatitis C by 2030, ensuring that treatments reach marginalized groups and are accessible to all those living with HCV will be crucial.”